Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Graham Holdings Company Common Stock (GHC) vs Inovio Pharmaceuticals Inc (INO) Price & Performance

Graham Holdings Company Common StockTrade
Inovio Pharmaceuticals IncTrade

Price performance (Past 24H)

Key statistics

Graham Holdings Company Common Stock vs Inovio Pharmaceuticals Inc — how do they compare? Graham Holdings Company Common Stock trades at $1,186.01 (market cap $5.02B), while Inovio Pharmaceuticals Inc trades at $1.18 (market cap $101.95M). The key difference: Graham Holdings Company Common Stock is far larger — about 49.2× Inovio Pharmaceuticals Inc's market cap, and Graham Holdings Company Common Stock pays a 0.63% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Graham Holdings Company Common Stock for 0 Days and Inovio Pharmaceuticals Inc for 43 Days on average.

GHCINO
Market Cap
$5.02B$101.95M
Volume
21,1182,985,847
Sector
IndustrialsHealth
52-Week High
$1.23K$2.60
52-Week Low
$949.84$0.66
Typical Hold Time
0 Days43 Days
Enterprise Value
$5.12B$73.28M
Dividend Yield
0.63%—

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Graham Holdings Company Common Stock

No Aura AI signal available yet.

Inovio Pharmaceuticals Inc

Inovio Pharmaceuticals (INO) trades at $0.9982, down 9.67% in the last session, with a bearish technical signal and negative financial metrics including a net income margin of -130,000%. The company shows consistent quarterly earnings beats but faces significant cash burn, with operating cash flow negative at -$88.63M in 2025. Key near-term catalyst is the FDA decision on INO-3107 expected by October 30, 2026.

INO presents high-risk speculative opportunity with analyst consensus price target of $2.75 representing 175% upside potential. The investment case hinges on successful FDA approval and commercialization of INO-3107, but carries substantial risk from persistent losses, negative cash flow, and dependence on financing activities to sustain operations.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

GHC
100% Buy0% Sell
Avg holding period · 0 Days
INO
97% Buy3% Sell
Avg holding period · 43 Days

About Graham Holdings Company Common Stock

Graham Holdings Company is a diversified holding company with operations spanning education services (Kaplan), television broadcasting (Graham Media Group), healthcare services, and manufacturing, among other businesses; it was formerly known as The Washington Post Company.

Read more on GHC →

About Inovio Pharmaceuticals Inc

Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.

Read more on INO →